Fate Therapeutics Inc
NASDAQ:FATE
Balance Sheet
Balance Sheet Decomposition
Fate Therapeutics Inc
Fate Therapeutics Inc
Balance Sheet
Fate Therapeutics Inc
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
6
|
9
|
54
|
49
|
65
|
89
|
89
|
191
|
100
|
167
|
134
|
61
|
42
|
36
|
|
| Cash Equivalents |
6
|
9
|
54
|
49
|
65
|
89
|
89
|
191
|
100
|
167
|
134
|
61
|
42
|
36
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
4
|
12
|
11
|
122
|
316
|
482
|
375
|
273
|
243
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
6
|
9
|
39
|
2
|
4
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
6
|
9
|
39
|
2
|
4
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
1
|
1
|
1
|
1
|
2
|
4
|
6
|
6
|
9
|
27
|
15
|
9
|
|
| Total Current Assets |
7
|
10
|
55
|
50
|
66
|
93
|
103
|
205
|
227
|
494
|
633
|
502
|
332
|
292
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
2
|
2
|
3
|
5
|
34
|
99
|
162
|
176
|
159
|
111
|
|
| PP&E Gross |
1
|
1
|
1
|
0
|
2
|
2
|
3
|
5
|
34
|
99
|
162
|
176
|
159
|
111
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
0
|
4
|
4
|
5
|
6
|
9
|
11
|
17
|
30
|
48
|
35
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
14
|
10
|
7
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
39
|
0
|
101
|
5
|
1
|
28
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
15
|
15
|
15
|
15
|
10
|
|
| Total Assets |
8
N/A
|
11
+41%
|
56
+401%
|
51
-8%
|
68
+33%
|
95
+40%
|
105
+11%
|
213
+102%
|
302
+42%
|
623
+106%
|
922
+48%
|
706
-23%
|
506
-28%
|
441
-13%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
2
|
2
|
1
|
1
|
1
|
1
|
2
|
4
|
6
|
6
|
9
|
8
|
5
|
9
|
|
| Accrued Liabilities |
0
|
0
|
2
|
2
|
2
|
4
|
7
|
11
|
16
|
19
|
48
|
60
|
34
|
29
|
|
| Short-Term Debt |
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
2
|
2
|
2
|
8
|
8
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
1
|
1
|
0
|
0
|
3
|
2
|
2
|
10
|
6
|
60
|
25
|
46
|
1
|
0
|
|
| Total Current Liabilities |
4
|
5
|
5
|
5
|
13
|
15
|
11
|
27
|
28
|
86
|
81
|
114
|
39
|
39
|
|
| Long-Term Debt |
4
|
2
|
0
|
18
|
11
|
3
|
15
|
12
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
1
|
1
|
0
|
0
|
6
|
4
|
2
|
13
|
30
|
152
|
161
|
108
|
99
|
83
|
|
| Total Liabilities |
8
N/A
|
7
-10%
|
5
-36%
|
23
+385%
|
30
+31%
|
22
-27%
|
28
+28%
|
53
+87%
|
58
+9%
|
238
+314%
|
243
+2%
|
222
-9%
|
138
-38%
|
122
-11%
|
|
| Equity | |||||||||||||||
| Common Stock |
50
|
57
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
51
|
66
|
87
|
112
|
142
|
176
|
219
|
285
|
384
|
557
|
769
|
1 051
|
1 212
|
1 398
|
|
| Additional Paid In Capital |
1
|
13
|
137
|
141
|
180
|
249
|
296
|
446
|
628
|
941
|
1 449
|
1 537
|
1 580
|
1 716
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
|
| Total Equity |
0
N/A
|
4
N/A
|
51
+1 273%
|
28
-44%
|
38
+34%
|
73
+93%
|
77
+5%
|
161
+108%
|
245
+53%
|
384
+57%
|
679
+77%
|
484
-29%
|
368
-24%
|
319
-13%
|
|
| Total Liabilities & Equity |
8
N/A
|
11
+41%
|
56
+401%
|
51
-8%
|
68
+33%
|
95
+40%
|
105
+11%
|
213
+102%
|
302
+42%
|
623
+106%
|
922
+48%
|
706
-23%
|
506
-28%
|
441
-13%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
19
|
19
|
20
|
21
|
29
|
41
|
53
|
65
|
76
|
88
|
96
|
97
|
99
|
114
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
3
|
3
|
3
|
|